| |||||||||||||||||||||
|
Recent Newsletters
Day 1 at ACC.23 features late-breaking studies on bempedoic acid, tricuspid valve repair & statins |
A warning from the FDA | Marijuana use & CAD | Choosing SAVR over TAVR | More from the last week! |
10 reasons to consider SAVR over TAVR | Cardiac POCUS in children | CLI treatment still evolving |
February's Most Popular Stories: Coronary IVL | Private equity & cardiology | ChatGPT | ICE & TEE | Much more |
FDA clears 2 new solutions, rules on omecamtiv mecarbil for HFrEF | AI model uses DNA to predict AFib, HF |
Medtronic & Abbott share new TAVR data | Addressing health disparities at the local level | A risky artificial sweetener |
FDA's warning about Trifecta heart valves | Heart attack deaths going down | A new-look device for PCI & TAVR |